At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 21 enrolled
Drug / intervention
THCvdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two-Phase, Randomized, Double-Blind, PlaceboControlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating THCv for Healthy Adults. Completed, enrolled 21 participants across 1 site.
Detailed Summary
This is a two-phase, randomized, double-blind, placebo-controlled, within-participant crossover study to assess the safety, tolerability, PK, and PD of five oral doses of CHI-915 versus placebo in healthy adult participants ages 18-55 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Adults
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartJan 2022
First PostedJan 2022
Primary CompletionMay 2022
TodayJul 2026
First PostedJan 27, 2022
Enrollment StartJan 11, 2022
Primary CompletionMay 6, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.4 years ago
Interventions
THCvdietary
THCv in MCT oil